Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Rating of “Moderate Buy” by Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been given an average rating of “Moderate Buy” by the eleven ratings firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $101.8571.

Several research firms have recently weighed in on LNTH. Mizuho lifted their price objective on Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. JonesTrading lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th.

Lantheus Stock Up 2.3%

Shares of NASDAQ:LNTH opened at $106.20 on Tuesday. The stock’s 50-day moving average price is $93.86 and its two-hundred day moving average price is $78.71. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. Lantheus has a 12-month low of $47.25 and a 12-month high of $107.99. The firm has a market cap of $6.91 billion, a price-to-earnings ratio of 25.59 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same period last year, the company earned $1.53 EPS. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts forecast that Lantheus will post 4.39 EPS for the current year.

Hedge Funds Weigh In On Lantheus

Several hedge funds and other institutional investors have recently modified their holdings of the company. Empowered Funds LLC acquired a new position in shares of Lantheus in the 1st quarter valued at about $909,000. Carmignac Gestion lifted its stake in shares of Lantheus by 18.4% in the 1st quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock valued at $100,729,000 after purchasing an additional 206,000 shares in the last quarter. Defilade Capital Management L.P. acquired a new position in shares of Lantheus in the 1st quarter valued at about $18,917,000. Parallel Advisors LLC lifted its stake in shares of Lantheus by 95.9% in the 1st quarter. Parallel Advisors LLC now owns 1,060 shares of the medical equipment provider’s stock valued at $80,000 after purchasing an additional 519 shares in the last quarter. Finally, Allen Capital Group LLC acquired a new position in shares of Lantheus in the 1st quarter valued at about $250,000. 99.06% of the stock is owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.